查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1800829

2025 年至 2033 年葡萄膜炎治療市場報告（依治療類型、疾病類型、病因、配銷通路和地區）

Uveitis Treatment Market Report by Treatment Type, Disease Type, Cause, Distribution Channel, and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 150 Pages | 商品交期: 2-3個工作天內

價格

2024年，全球葡萄膜炎治療市場規模達18億美元。展望未來， IMARC Group預計到2033年，該市場規模將達到27億美元，2025-2033年期間的複合年成長率（CAGR）為4.44%。受以下因素推動，該市場正在經歷顯著成長：葡萄膜炎發病率的上升；各種生物製劑和免疫抑制療法的持續研發活動，旨在豐富治療方案；對提高認知度和早期診斷的重視；政府的優惠政策以及醫療報銷政策。

葡萄膜炎治療市場趨勢：

自體免疫疾病盛行率不斷上升

全球自體免疫疾病的發生率不斷上升，刺激了對葡萄膜炎治療的需求。根據美國國立衛生研究院 (NIH) 報告，估計有 2,350 萬美國人患有自體免疫疾病，這些疾病包括類風濕性關節炎、發炎性腸道疾病、狼瘡等，並最終發展為葡萄膜炎。值得注意的是，這種盛行率證明了對針對自體免疫疾病的有效葡萄膜炎療法的需求很高，並刺激了市場需求。因此，隨著這些疾病在世界各地的蔓延，治療的目標是控制葡萄膜炎及其相關症狀，並針對導致疾病的自身免疫過程，從而改善患者的生活。

生物製劑和免疫療法的進展

生物製劑和免疫調節療法透過調節免疫介導過程，徹底改變了葡萄膜炎的治療。美國國立衛生研究院 (NIH) 已批准多種用於治療自體免疫疾病（例如葡萄膜炎）的生物製劑，這標誌著人們正轉向使用經濟高效的生物製劑。此類療法的優點在於，與皮質類固醇等其他療法相比，其副作用對身體其他器官的影響機率更低，從而提高了患者對推薦治療方案的依從性。因此，生物技術和免疫學市場的持續發展促進了生物製劑和免疫調節劑產品的開發，從而擴大了全球市場中葡萄膜炎治療的機會。

醫療支出和研究經費不斷增加

政府在醫療體系方面的支出增加、發展策略以及醫療保健領域的進步，正在推動葡萄膜炎治療市場的價值成長。在美國，美國國立衛生研究院 (NIH) 為研究葡萄膜炎和其他自體免疫疾病提供大量資金，這項研究是大學、製藥業和醫院之間多部門、多方合作的成果。這些資金支持進一步推動了葡萄膜炎新療法的進展，因為它推動了新藥、生物製劑和治療方法的發展。此外，政府資助的研究經費和臨床試驗提供了必要的框架和資源，以支持探索新的治療方法並驗證治療的有效性。這些動態使得葡萄膜炎治療市場高度依賴研究，因為它致力於將新發現轉化為臨床有用的產品和服務，以滿足現有需求並提升全球患者體驗。

葡萄膜炎治療市場細分：

依治療類型分類：

  • 皮質類固醇
  • 免疫抑制劑
  • 單株抗體
  • 睫狀肌麻痺劑
  • 抗生素
  • 抗病毒藥物
  • 抗真菌
  • 止痛藥

皮質類固醇佔大部分市場佔有率

根據葡萄膜炎治療市場預測，皮質類固醇在葡萄膜炎治療市場中佔據主導地位，因為它們有助於減輕發炎並維持患者視力。美國國立衛生研究院 (NIH) 報告稱，皮質類固醇是治療葡萄膜炎的主要藥物，因為它們能夠快速控制發炎以及不同類型葡萄膜炎（前葡萄膜炎、後葡萄膜炎和全葡萄膜炎）的症狀。這些藥物的主要適應症是降低身體抵抗眼部感染的能力並減輕炎症，從而快速有效地緩解症狀並改善患者的健康狀況。皮質類固醇可以透過眼藥水、注射和口服藥片給藥，這取決於病情嚴重程度和患者的具體情況。由於皮質類固醇可能存在副作用，包括長期使用會導致眼壓升高和術後白內障形成，因此它們仍然比其他競爭對手更受歡迎，而中等療效的局部非類固醇抗發炎藥物 (NSAID) 儘管在眼科實踐中經常使用，但在葡萄膜炎治療中卻不那麼受歡迎。

依疾病類型分類：

  • 前葡萄膜炎
  • 後葡萄膜炎
  • 中間葡萄膜炎
  • 全葡萄膜炎

前葡萄膜炎佔業界最大佔有率

前葡萄膜炎因其發病率較高且需要特殊治療，在葡萄膜炎治療領域佔據領先地位。美國國立衛生研究院 (NIH) 將前葡萄膜炎歸類為最常見的葡萄膜炎類型，占美國已報告所有葡萄膜炎病例的 50-60%。前葡萄膜炎是由眼球前部結構（稱為葡萄膜）的發炎引起的，與自體免疫疾病、感染或身體損傷有關。因此，這種模式意味著前葡萄膜炎的治療需要不同的管理策略，例如局部使用皮質類固醇和擴瞳劑，這些藥物在診所、眼科和零售店均有常規使用，從而創造了良好的市場前景。

分手原因：

  • 傳染性
  • 非傳染性

非傳染性藥物佔主要市場佔有率

非感染性葡萄膜炎治療市場收入主要來自非感染性葡萄膜炎，因為這種疾病比感染性葡萄膜炎更常見，並且可以透過改進的實證個別化治療來應對自體免疫和發炎過程。根據美國國立衛生研究院 (NIH) 的數據，非感染性葡萄膜炎約占美國所有葡萄膜炎病例的 80% 至 90%。這種類型的葡萄膜炎與自體免疫疾病（例如類風濕性關節炎、發炎性腸道疾病、狼瘡）以及對生物製劑和免疫調節劑的需求更為相關。世界各地的研究人員觀察到，自體免疫疾病的病例正在持續增加，這增強了非感染性葡萄膜炎治療的市場地位。現代製藥業致力於開發合適的個人化抗葡萄膜炎製劑，以更有效地針對非感染性葡萄膜炎的免疫致病背景，同時最大程度地減少全身給藥的副作用，從而為葡萄膜炎治療市場創造了良好的前景。

依配銷通路分類：

  • 醫院藥房
  • 零售藥局
  • 網路藥局
  • 其他

零售藥局在市場上佔據明顯主導地位

零售藥局在葡萄膜炎治療市場佔有最大佔有率，主要是因為它們易於取得且便捷，尤其是對患者而言，而且它們也參與藥品調配。美國社區藥劑師協會 (NCPA) 報告稱，美國零售藥局調配了約 72% 的處方，這凸顯了藥劑師在藥物調配中的核心地位。這份葡萄膜炎治療市場概覽顯示，確診患有葡萄膜炎的患者可以從零售藥局以更快的速度便捷地獲得處方藥，例如皮質類固醇、免疫抑制劑和生物製劑。此外，零售藥局也提供病患諮詢、藥物和健康保險資訊及管理，從而提高了病患的滿意度和治療效果。利害關係人透過它們與醫療系統和電子健康記錄進行交互，從而為葡萄膜炎患者提供持續的護理。由於零售藥局服務日益多樣化，以及對患者和消費者的關注日益加深，它們在滿足市場對葡萄膜炎藥物日益成長的需求和主導藥品分銷方面做出了巨大貢獻。

按地區分類：

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

北美引領市場，佔據葡萄膜炎治療市場最大佔有率

該報告還對所有主要區域市場進行了全面分析，包括北美（美國和加拿大）、亞太地區（中國、日本、印度、韓國、澳洲、印尼等）、歐洲（德國、法國、英國、義大利、西班牙、俄羅斯等）、拉丁美洲（巴西、墨西哥等）以及中東和非洲。報告指出，北美是葡萄膜炎治療最大的區域市場。

根據葡萄膜炎治療市場報告，北美憑藉其發達先進的醫療保健產業、對新型治療方案的接受度以及對研發的直接投入，佔據最大的市場佔有率。根據美國國立衛生研究院 (NIH) 報告，僅在美國，自體免疫疾病研究的預算就已相當可觀，並且為進行大量臨床試驗以及各製藥實體、研究機構和護理人員之間的合作提供了有利的環境。此類策略性投資使北美國家能夠在生物製劑、免疫調節劑和其他治療葡萄膜炎的方法的開發和商業化方面佔據領先地位。此外，由於自體免疫疾病（後來發展為葡萄膜炎）的發生率較高，北美地區需要高效的葡萄膜炎治療和管理，從而佔據全球葡萄膜炎市場的領導地位。

（請注意，這只是關鍵參與者的部分列表，完整列表在報告中提供。）

  • 專注於葡萄膜炎治療藥物研發的製藥公司和研究機構正透過臨床試驗來應對葡萄膜炎疾病發展過程中的各種挑戰。艾伯維、諾華和艾爾建等市場領導者致力於研發針對葡萄膜炎發展特定免疫過程的新藥。例如，艾伯維的研究策略包括近期的合作和臨床試驗，探索生物製劑在自體免疫性葡萄膜炎中的應用，體現了其對精準醫療的重視。許多此類活動由政府和研究機構資助，旨在促進產學合作，在葡萄膜炎治療模式轉變的背景下推進治療進展並改善患者護理，從而推動葡萄膜炎治療行業的發展。

本報告回答的關鍵問題

  • 2024 年全球葡萄膜炎治療市場規模是多少
  • 2025-2033年全球葡萄膜炎治療市場的預期成長率是多少
  • COVID-19 對全球葡萄膜炎治療市場有何影響
  • 推動全球葡萄膜炎治療市場的關鍵因素有哪些
  • 根據治療類型，全球葡萄膜炎治療市場如何分類
  • 根據疾病類型，全球葡萄膜炎治療市場如何分類
  • 全球葡萄膜炎治療市場按病因分類如何
  • 根據配銷通路，全球葡萄膜炎治療市場如何分佈
  • 全球葡萄膜炎治療市場的主要區域有哪些
  • 10. 全球葡萄膜炎治療市場的主要參與者/公司有哪些？

本報告回答的關鍵問題

  • 2024年全球葡萄膜炎治療市場規模？ 2025-2033年全球葡萄膜炎治療市場的預期成長率是多少？
  • COVID-19 對全球葡萄膜炎治療市場有何影響？
  • 推動全球葡萄膜炎治療市場發展的關鍵因素有哪些？
  • 根據治療類型，全球葡萄膜炎治療市場如何分佈？
  • 根據疾病類型，全球葡萄膜炎治療市場是如何分佈的？
  • 全球葡萄膜炎治療市場依病因分為哪些類型？
  • 根據配銷通路，全球葡萄膜炎治療市場如何分佈？
  • 全球葡萄膜炎治療市場的主要地區有哪些？
  • 全球葡萄膜炎治療市場的主要參與者/公司有哪些？

目錄

第1章：前言

第2章：範圍與方法

  • 研究目標
  • 利害關係人
  • 資料來源
    • 主要來源
    • 次要來源
  • 市場評估
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章：執行摘要

第4章：簡介

第5章：全球葡萄膜炎治療市場

  • 市場概覽
  • 市場表現
  • COVID-19的影響
  • 市場預測

第6章：市場區隔：依治療類型

  • 皮質類固醇
  • 免疫抑制劑
  • 單株抗體
  • 睫狀肌麻痺劑
  • 抗生素
  • 抗病毒藥物
  • 抗真菌
  • 止痛藥

第7章：市場區隔：依疾病類型

  • 前葡萄膜炎
  • 後葡萄膜炎
  • 中間葡萄膜炎
  • 全葡萄膜炎

第8章：市場分化：依原因

  • 傳染性
  • 非傳染性

第9章：市場區隔：按配銷通路

  • 醫院藥房
  • 零售藥局
  • 網路藥局
  • 其他

第10章：市場細分：按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第 11 章：SWOT 分析

第 12 章：價值鏈分析

第 13 章：波特五力分析

第 14 章：價格分析

第 15 章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • AbbVie Inc.
    • Alimera Sciences Inc.
    • Bausch & Lomb Incorporated (Bausch Health)
    • Enzo Biochem Inc.
    • Eyegate Pharmaceuticals Inc.
    • Eyepoint pharmaceuticals Inc.
    • Novartis AG
    • Regeneron Pharmaceuticals Inc
    • Santen Pharmaceutical Co. Ltd.
Product Code: SR112025A2759

The global uveitis treatment market size reached USD 1.8 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 2.7 Billion by 2033, exhibiting a growth rate (CAGR) of 4.44% during 2025-2033. The market is experiencing significant growth driven by the rising incidence of uveitis, ongoing research and development activities in various biologics and immunosuppressive treatments to diversify treatment possibilities, heightening emphasis on increasing awareness and early diagnosis, favorable government policies, and healthcare reimbursements.

Uveitis Treatment Market Trends:

Increasing Prevalence of Autoimmune Diseases

The uveitis treatment demand is stimulated by the increased rate of autoimmune diseases all over the world. As reported by the National Institutes of Health (NIH), autoimmune diseases are estimated to affect 23.5 million Americans, who have rheumatoid arthritis, inflammatory bowel disease, and lupus among other diseases develop uveitis as a sequel. It is important to note that this prevalence proves the high requirement for efficient uveitis therapies targeted at autoimmune diseases and stimulating the demand in the market. Thus, as these diseases move high across the world, treatment aims for uveitis and its therapies controlling the symptoms and it addresses the autoimmune processes that cause the disease to achieve better results in patients' lives.

Advancements in Biologics and Immunotherapy Therapies

Biologics and immunomodulatory therapies have revolutionized uveitis management by modulation of immune-mediated processes. The National Institutes of Health (NIH) has approved various biologics for autoimmune diseases, such as uveitis, signifying the change towards the use of cost-effective and effective biologics. Such therapies have benefits such as lower probability of side effects affecting other organs in the body than other treatments like corticosteroids which in turn is witnessing patients being more compliant to the treatment regimens that are recommended to them. As a result, there are continued markets in biotechnology and immunology leading to product development in biologics and immunomodulators extending the opportunities for the treatment of uveitis in the global market.

Rising Healthcare Expenditure and Research Funding

Increased government spending in healthcare systems, development strategies, and advances in healthcare are fueling the uveitis treatment market value. In the USA, the NIH supports significant funding to investigate uveitis and other auto-immune disorders, and this research has been a multisectoral and multiparty cooperation among universities, pharmaceutical industries, and hospitals. This financial support further brings a positive change to the progression of new treatments for uveitis as it pushes the development of new drugs, biologics, and treatment methods. Moreover, research grants and clinical trials that are supported by the government offer essential frameworks and resources to support the exploration of novel therapeutic profiles and verify the effectiveness of treatments. These dynamics make the uveitis treatment market highly research-intensive, as it capitalizes on the conversion of discoveries into clinically useful products and services that address existing requirements and enhance patient experience worldwide.

Uveitis Treatment Market Segmentation:

Breakup by Treatment Type:

  • Corticosteroids
  • Immunosuppressant
  • Monoclonal Antibodies
  • Cycloplegic Agents
  • Antibiotics
  • Antivirals
  • Antifungal
  • Analgesics

Corticosteroids account for the majority of the market share

As per the uveitis treatment market forecast, Corticosteroids thus dominate the uveitis treatment market by share since they help reduce inflammation and maintain vision in affected individuals. The National Institutes of Health (NIH) reported that corticosteroids are the primary therapy for uveitis, as they yield fast control of inflammation and signs about different uveitis types, anterior, posterior, and panuveitis. The main indications for these medicines are to lessen the body's ability to fight infection in the eye and diminish inflammation, which provides fast and effective relief and enhances the degree of patient's health. Corticosteroids can be administered through eye drops, injections, and oral tablets depending on the intensity of the situation and condition of the patient. As corticosteroids present possible side-effects, including rising intraocular pressure and postoperative cataract formation by long-term application, they remain preferred to other competitors while moderately effective topical NSAIDs are not as popular in uveitis treatment despite frequent use in ophthalmological practice.

Breakup by Disease Type:

  • Anterior Uveitis
  • Posterior Uveitis
  • Intermediate Uveitis
  • Panuveitis

Anterior uveitis holds the largest share of the industry

Anterior uveitis holds a leading position in the segmentation of uveitis treatment because of its greater incidence and the necessity of unique therapy. The National Institutes of Health (NIH) categorizes anterior uveitis as the most prevalent type of uveitis which accounts for 50-60% of all uveitis reported in the United States. This is caused by inflammation of the structures of the anterior part of the eye known as the uvea, it is linked with autoimmune diseases, infections, or physical injury. As a result, the pattern implies the treatment of anterior uveitis requires different management strategies such as topical corticosteroids and pupil-dilating agents available, routinely managed in clinics or ophthalmology and retail outlets, thus creating a favorable

Breakup by Cause:

  • Infectious
  • Non-infectious

Non-infectious represents the leading market segment

Non-infectious drive the uveitis treatment market revenue as the condition is more frequent than the infection-related kind and was addressed using improving evidence-based individualized treatment targeting autoimmune and inflammation processes. According to the National Institutes of Health (NIH), non-infectious uveitis accounts for approximately 80-90% of all uveitis cases in the United States. This form of uveitis is more related to autoimmune diseases such as rheumatoid arthritis, inflammatory bowel disease, lupus, and the need for biologics and immunomodulatory agents. It has been observed by researchers from across the world that the cases of autoimmune diseases are continuously increasing, which strengthens the market position of the non-infectious forms of uveitis treatments. The modern pharmaceutical industry concentrates on the development of proper individual antiretirologic preparations to target more effectively the immunopathogenetic background of non-infectious uveitis with minimal side effects from systemic administration, thus creating a favorable uveitis treatment market outlook.

Breakup by Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

Retail pharmacies exhibit a clear dominance in the market

Retail pharmacies hold the largest market share of uveitis treatment primarily because they are easily accessible, and convenient, especially to the patients and they also engage in the dispensing of drugs. The National Community Pharmacists Association (NCPA) repoted that retail pharmacies in the United States dispense about 72% of prescriptions emphasizing the centrality of pharmacists in dispensing of medication. This uveitis treatment market overview shows that patients diagnosed with uveitis can conveniently get prescribed medicines such as corticosteroid, immunosuppressant, and biologic agents from the retail pharmacy at a faster pace. Additionally, retail pharmacies involve patient counseling, medication and health insurance information and management, which improves patient satisfaction and outcomes. Stakeholders use them to interface with the health systems and electronic health records, thereby providing continuity of care to patients with uveitis. Due to increased diversification of services and sophisticated patient and consumer focus in retail pharmacy, they significantly contribute to meeting the increasing needs of the market for uveitis medications and dominating the distribution of drugs.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America leads the market, accounting for the largest uveitis treatment market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia and others), Latin America (Brazil Mexico, and others) and the Middle East and Africa. According to the report, North America was the largest regional market for uveitis treatment.

As per the uveitis treatment market report, North America holds the largest market share due to its well-developed and advanced healthcare sector, acceptance of novel therapeutic management, and direct spending on research and development. As reported by the National Institutes of Health (NIH), a significant budget is devoted to autoimmune disease studies in the United States alone and there exists a conducive environment for numerous clinical trials and partnerships among various pharmaceutical entities, research institutions, and caregivers. Such strategic investment allows North American countries to take a frontline in the development and commercialization of biologics, immunomodulatory, and other approaches to treating uveitis. Also, presenting a higher frequency of autoimmune diseases which later develop into uveitis, the North American region needs efficient uveitis treatment and management, thereby carrying the market leadership of the global uveitis market.

Competitive Landscape:

  • The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the uveitis treatment industry include AbbVie Inc., Alimera Sciences Inc., Bausch & Lomb Incorporated (Bausch Health), Enzo Biochem Inc., Eyegate Pharmaceuticals Inc., Eyepoint Pharmaceuticals Inc., Novartis AG, Regeneron Pharmaceuticals Inc., and Santen Pharmaceutical Co. Ltd.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

  • The uveitis treatment companies are focusing on the development of uveitis treatment include pharmaceutical companies and research institutions to meet the various challenges presented by the uveitis disease process through clinical trials. The market leaders such as AbbVie, Novartis, and Allergan are committed to research and development to launch new drugs that address specific immunological processes of uveitis development. For instance, the research strategies of AbbVie involve recent collaborations and clinical trials that explore the usage of biologics for autoimmune uveitis, proving the focus on precision medicine. Many of these activities are funded through government and research grants that promote academic-industry collaboration to advance therapeutic progress and improve patients' care in the context of the shifting uveitis treatment paradigm, thus fueling uveitis treatment industry growth.

Key Questions Answered in This Report

  • 1.What was the size of the global uveitis treatment market in 2024?
  • 2.What is the expected growth rate of the global uveitis treatment market during 2025-2033?
  • 3.What has been the impact of COVID-19 on the global uveitis treatment market?
  • 4.What are the key factors driving the global uveitis treatment market?
  • 5.What is the breakup of the global uveitis treatment market based on the treatment type?
  • 6.What is the breakup of the global uveitis treatment market based on the disease type?
  • 7.What is the breakup of the global uveitis treatment market based on the cause?
  • 8.What is the breakup of the global uveitis treatment market based on the distribution channel?
  • 9.What are the key regions in the global uveitis treatment market?
  • 10.Who are the key players/companies in the global uveitis treatment market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Uveitis Treatment Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Treatment Type

  • 6.1 Corticosteroids
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Immunosuppressant
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Monoclonal Antibodies
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Cycloplegic Agents
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Antibiotics
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Antivirals
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast
  • 6.7 Antifungal
    • 6.7.1 Market Trends
    • 6.7.2 Market Forecast
  • 6.8 Analgesics
    • 6.8.1 Market Trends
    • 6.8.2 Market Forecast

7 Market Breakup by Disease Type

  • 7.1 Anterior Uveitis
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Posterior Uveitis
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Intermediate Uveitis
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Panuveitis
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Cause

  • 8.1 Infectious
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Non-infectious
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by Distribution Channel

  • 9.1 Hospital Pharmacies
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Retail Pharmacies
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Online Pharmacies
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Others
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 AbbVie Inc.
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Alimera Sciences Inc.
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
    • 15.3.3 Bausch & Lomb Incorporated (Bausch Health)
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 SWOT Analysis
    • 15.3.4 Enzo Biochem Inc.
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 Eyegate Pharmaceuticals Inc.
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
    • 15.3.6 Eyepoint pharmaceuticals Inc.
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
    • 15.3.7 Novartis AG
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Regeneron Pharmaceuticals Inc
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Santen Pharmaceutical Co. Ltd.
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Uveitis Treatment Market: Major Drivers and Challenges
  • Figure 2: Global: Uveitis Treatment Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Uveitis Treatment Market: Breakup by Treatment Type (in %), 2024
  • Figure 4: Global: Uveitis Treatment Market: Breakup by Disease Type (in %), 2024
  • Figure 5: Global: Uveitis Treatment Market: Breakup by Cause (in %), 2024
  • Figure 6: Global: Uveitis Treatment Market: Breakup by Distribution Channel (in %), 2024
  • Figure 7: Global: Uveitis Treatment Market: Breakup by Region (in %), 2024
  • Figure 8: Global: Uveitis Treatment Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 9: Global: Uveitis Treatment (Corticosteroids) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 10: Global: Uveitis Treatment (Corticosteroids) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 11: Global: Uveitis Treatment (Immunosuppressant) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 12: Global: Uveitis Treatment (Immunosuppressant) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 13: Global: Uveitis Treatment (Monoclonal Antibodies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 14: Global: Uveitis Treatment (Monoclonal Antibodies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 15: Global: Uveitis Treatment (Cycloplegic Agents) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 16: Global: Uveitis Treatment (Cycloplegic Agents) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 17: Global: Uveitis Treatment (Antibiotics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 18: Global: Uveitis Treatment (Antibiotics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 19: Global: Uveitis Treatment (Antivirals) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 20: Global: Uveitis Treatment (Antivirals) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 21: Global: Uveitis Treatment (Antifungal) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 22: Global: Uveitis Treatment (Antifungal) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 23: Global: Uveitis Treatment (Analgesics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 24: Global: Uveitis Treatment (Analgesics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 25: Global: Uveitis Treatment (Anterior Uveitis) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 26: Global: Uveitis Treatment (Anterior Uveitis) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 27: Global: Uveitis Treatment (Posterior Uveitis) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 28: Global: Uveitis Treatment (Posterior Uveitis) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 29: Global: Uveitis Treatment (Intermediate Uveitis) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 30: Global: Uveitis Treatment (Intermediate Uveitis) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 31: Global: Uveitis Treatment (Panuveitis) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 32: Global: Uveitis Treatment (Panuveitis) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 33: Global: Uveitis Treatment (Infectious) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 34: Global: Uveitis Treatment (Infectious) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 35: Global: Uveitis Treatment (Non-infectious) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 36: Global: Uveitis Treatment (Non-infectious) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 37: Global: Uveitis Treatment (Hospital Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 38: Global: Uveitis Treatment (Hospital Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 39: Global: Uveitis Treatment (Retail Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 40: Global: Uveitis Treatment (Retail Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 41: Global: Uveitis Treatment (Online Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 42: Global: Uveitis Treatment (Online Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 43: Global: Uveitis Treatment (Other Distribution Channels) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 44: Global: Uveitis Treatment (Other Distribution Channels) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 45: North America: Uveitis Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 46: North America: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 47: United States: Uveitis Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 48: United States: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 49: Canada: Uveitis Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 50: Canada: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 51: Asia Pacific: Uveitis Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 52: Asia Pacific: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 53: China: Uveitis Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 54: China: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 55: Japan: Uveitis Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 56: Japan: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 57: India: Uveitis Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 58: India: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 59: South Korea: Uveitis Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 60: South Korea: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 61: Australia: Uveitis Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 62: Australia: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 63: Indonesia: Uveitis Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 64: Indonesia: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 65: Others: Uveitis Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 66: Others: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 67: Europe: Uveitis Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 68: Europe: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 69: Germany: Uveitis Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 70: Germany: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 71: France: Uveitis Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 72: France: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 73: United Kingdom: Uveitis Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 74: United Kingdom: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 75: Italy: Uveitis Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 76: Italy: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 77: Spain: Uveitis Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 78: Spain: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 79: Russia: Uveitis Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 80: Russia: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 81: Others: Uveitis Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 82: Others: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 83: Latin America: Uveitis Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 84: Latin America: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 85: Brazil: Uveitis Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 86: Brazil: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 87: Mexico: Uveitis Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 88: Mexico: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 89: Others: Uveitis Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 90: Others: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 91: Middle East and Africa: Uveitis Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 92: Middle East and Africa: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 93: Global: Uveitis Treatment Industry: SWOT Analysis
  • Figure 94: Global: Uveitis Treatment Industry: Value Chain Analysis
  • Figure 95: Global: Uveitis Treatment Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Uveitis Treatment Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Uveitis Treatment Market Forecast: Breakup by Treatment Type (in Million USD), 2025-2033
  • Table 3: Global: Uveitis Treatment Market Forecast: Breakup by Disease Type (in Million USD), 2025-2033
  • Table 4: Global: Uveitis Treatment Market Forecast: Breakup by Cause (in Million USD), 2025-2033
  • Table 5: Global: Uveitis Treatment Market Forecast: Breakup by Distribution Channel (in Million USD), 2025-2033
  • Table 6: Global: Uveitis Treatment Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 7: Global: Uveitis Treatment Market Structure
  • Table 8: Global: Uveitis Treatment Market: Key Players